Latest period
$148.09M
YoY change
-24.3%
5Y CAGR
+49.4%
Peak year (2024)
$211.88M
Latest annual
$160.47M
Total Equity history chart for Climb Bio (CLYM) from 2019 to 2025
Latest: $160.47M
Total Equity growth chart for Climb Bio (CLYM) from 2019 to 2025
Latest: -24.3%
Total Equity history table for Climb Bio (CLYM) from 2019 to 2025
| 2025 | $160.47M | -24.3% | −$51.41M | ||
| 2024 | $211.88M | +96.9% | +$104.28M | ||
| 2023 | $107.60M | -16.4% | −$21.12M | ||
| 2022 | $128.72M | -23.0% | −$38.49M | ||
| 2021 | $167.20M | +675.2% | +$145.63M | ||
| 2020 | $21.57M | +4.6% | +$956.00K | ||
| 2019 | $20.61M | — | — |
- 2025$160.47M-24.3%
- 2024$211.88M+96.9%
- 2023$107.60M-16.4%
- 2022$128.72M-23.0%
- 2021$167.20M+675.2%
- 2020$21.57M+4.6%
- 2019$20.61M—
Total Equity values are taken from Climb Bio's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Equity at Climb Bio (CLYM)
According to Climb Bio's latest reported financial statements, the company's latest reported total equity is $148.09M. Net assets — also called stockholders' equity — equal total assets minus total liabilities. They represent the residual claim of shareholders on the company's assets and roughly track book value over time.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual total equity for Climb Bio (CLYM) came in at $160.47M – declined 24.3% year-over-year.
Across 2020–2025 (5 years), Climb Bio total equity produced a CAGR of +49.4% – with mixed annual results across the window.
Climb Bio total equity peaked at $211.88M in 2024; the latest annual figure is $160.47M in 2025 (24.3% below peak).
Across the available history, total equity reached its high of $211.88M in 2024 and its low of $20.61M in 2019.
Climb Bio Total Equity by Year
Climb Bio Total Equity 2025: $160.47M
Climb Bio total equity in 2025 was $160.47M, declined 24.3% below 2024.
Climb Bio Total Equity 2024: $211.88M
2024's total equity for Climb Bio came in at $211.88M, surged 96.9% from 2023. This figure represents the highest annual value in the available history.
Climb Bio Total Equity 2023: $107.60M
Climb Bio posted total equity of $107.60M in 2023, declined 16.4% below 2022.
Climb Bio Total Equity 2022: $128.72M
In 2022, Climb Bio reported total equity of $128.72M, declined 23.0% below 2021.
Climb Bio Total Equity 2021: $167.20M
Climb Bio total equity in 2021 was $167.20M.
See more financial history for Climb Bio (CLYM).
Sector peers by Total Equity
Healthcare peers of Climb Bio (CLYM), ranked by their latest total equity
| $94.11B | |
| $81.54B | |
| $52.61B | |
| $48.67B | |
| $30.52B | |
| $26.54B | |
| $8.66B | |
| −$3.27B |
- $94.11B
- $81.54B
- $52.61B
- $48.67B
- $30.52B
- $26.54B
- $8.66B
- −$3.27B
Frequently asked questions
Climb Bio (CLYM) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation